Cargando…
Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal
Autores principales: | Thein, Swee Lay, Pirenne, France, Fasano, Ross M., Habibi, Anoosha, Bartolucci, Pablo, Chonat, Satheesh, Hendrickson, Jeanne E., Stowell, Sean R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049330/ https://www.ncbi.nlm.nih.gov/pubmed/32029505 http://dx.doi.org/10.3324/haematol.2019.224709 |
Ejemplares similares
-
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease
por: Floch, Aline, et al.
Publicado: (2020) -
Transfusion therapy for sickle cell disease: what’s new?
por: Chou, Stella T., et al.
Publicado: (2022) -
Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
por: Mpinganzima, Clarisse, et al.
Publicado: (2020) -
Initiation and Regulation of Complement during Hemolytic Transfusion Reactions
por: Stowell, Sean R., et al.
Publicado: (2012) -
Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)